Details for Patent: 8,039,504

Which drugs does patent 8,039,504 protect, and when does it expire?

Patent 8,039,504 protects TPOXX and is included in two NDAs.

This patent has thirty-five patent family members in thirteen countries.

Summary for Patent: 8,039,504

Title:	Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
Abstract:	Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.
Inventor(s):	Jordan; Robert F. (Corvallis, OR), Bailey; Thomas R. (Phoenixville, PA), Rippin; Susan R. (Wilmington, DE), Dai; Dongcheng (Corvallis, OR)
Assignee:	Siga Technologies, Inc. (New York, NY)
Application Number:	11/785,998
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 8,039,504

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Siga Technologies	TPOXX	tecovirimat	CAPSULE;ORAL	208627-001	Jul 13, 2018		RX	Yes	Yes			Y
Siga Technologies	TPOXX	tecovirimat	SOLUTION;INTRAVENOUS	214518-001	May 18, 2022		RX	Yes	Yes			Y

International Family Members for US Patent 8,039,504

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1638938		301177	Netherlands
European Patent Office	1638938		2022C/521	Belgium
European Patent Office	1638938		122022000032	Germany
European Patent Office	1638938		2290024-5	Sweden
European Patent Office	1638938		C202230021	Spain
Australia	2004249250